Randomized trial evaluates effectiveness of China's medical research integrity policies, suggesting improvements for better governance.
Objective To quantitatively evaluate China's core research integrity policies by constructing an evaluation index system specific to the medical field and reveal the applicability and structural shortcomings of these policies,thereby providing empirical evidence and optimization pathways for enhancing the scientific rigor and practical effectiveness of research integrity governance in China. Methods Eighteen research integrity policy documents issued at the national level by the central government and ministries from January 2010 to January 2025 were collected.An evaluation framework based on the policy modeling consistency index model was constructed via text mining and keyword analysis to quantitatively assess the consistency and effectiveness of these policies.According to their scores,the policies were rated as excellent,good,medium,or bad grade. Results The 18 policies showed the average policy modeling consistency index of 6.27 and the sag index of 2.73,which indicated good overall performance but with clear disparities.Among them,3 policies were rated as excellent,6 as good,and 9 as medium.Analysis of the dimensional averages revealed that while the policies performed robustly in terms of policy function and policy timeliness,they exhibited significant shortcomings in the dimensions of policy target and policy scope,with average scores of 0.59 and 0.44,respectively. Conclusions While China's medical research integrity policy framework is generally effective,it exhibits clear structural shortcomings,including a lack of international perspective,monolithic policy targets,insufficient enforcement rigidity,and low operability.Accordingly,it is recommended that measures such as aligning with global standards,establishing a multi-stakeholder collaborative governance network,strengthening policy enforcement,and improving policy operability should be adopted.These measures will help to systematically optimize China's medical research integrity policy system,thereby enhancing the overall governance level in this domain.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: